Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — Lazard 8th Annual Healthcare Conference (November 2011)
34 slides from Biolase's conference presentation, Nov 17, 2011
Slide 1: Lazard 8th Annual Healthcare Conference - BIOLASE Technology, Inc.
EXHIBIT 99.1 LAZARDth8 Annual Healthcare Conference November 15-16, 2011, New York , NY BIOLASE Technology, Inc. Fred Furry, COO/CFO NASDAQ: BLTI www.biolase.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “e
Slide 3: BIOLASE is a True Turnaround Story
BIOLASE is a True Turnaround Story How BIOLASE is positioned for a successful recovery: • Effective August 2010, BIOLASE changed direction with a new CEO and a fully reconstituted Board of Directors. As a result, BIOLASE has a better organizational structure, better cost control, and is more effecti
Slide 4: BIOLASE is NOT Just Another Medical Equipment Company!
BIOLASE is NOT Just Another Medical Equipment Company! BIOLASE is revolutionizing surgery by breaking the limitations of conventional dentistry and medicine. New management is transforming BIOLASE from a one product, one segment company of the past to a multi- product and multi-segment platform comp
Slide 5: How is BIOLASE Revolutionizing Surgery?
How is BIOLASE Revolutionizing Surgery? …through the science of WaterLase! Conventional Surgical Devices include the scalpel, high speed drill, electrosurge, electric bone saws, and heat generating lasers. Yearsofengineering andresearchatBIOLASE ledto thediscoverythattheEr,Cr:YSGG(2796nm)laser cryst
Slide 6: BIOLASE is the World Leader in Laser Dentistry
BIOLASE is the World Leader in Laser Dentistry… …and the Dental Community is the Largest Medical Community World!in the 2009 US Dental Laser Market: 2009 US Overall Dental Laser Market: Hard Hard Tissue & Soft Tissue BIOLASE 45% BIOLASE 80% Source: Biolase Technology Licensing Reports Source: iData
Slide 7: Current Line of BIOLASE Products
Current Line of BIOLASE Products All-tissue dental lasers: Our all-tissue lasers include our new flagship laser, the revolutionary WaterLase iPlus, and the WaterLase MD Turbo. Diode soft-tissue dental lasers: Oursofttissuelasers include the ezLase total diode solution, which offers power and portabi
Slide 8: Traditional Dentistry
Traditional Dentistry The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608 PAGE 8
Slide 9: Alternative and Advanced Hi-Tech Dentistry
Alternative and Advanced Hi-Tech Dentistry Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System: The iPlus features an The aiming beam on intuitive, touch-based the NEW WaterLase computer screen, iPlus is green. This similar to a tablet red beam featured in personal computer. th
Slide 10: WaterLase High Speed Cutting
WaterLase High Speed Cutting PAGE 10
Slide 11: WaterLase vs. Drill
WaterLase vs. Drill BIOUASE BIOLASE
Slide 12: Becoming a Globally Diversified Platform Company
Becoming a Globally Diversified Platform Company In 2011: Single Product Company In 2012: Broaden Platform and Product Portfolio 1. Moved from exclusive distribution with Schein1. Diversify revenue base to expand addressable to direct sales and multi-distributor model. markets and reduce investor ri
Slide 13: Why BIOLASE WaterLase Technology in Dentistry?
Why BIOLASE WaterLase Technology in Dentistry? Traditional high-speed drillsworkbyFRICTION whichcreatesHEATwhichcausesPAIN. This PAINnecessitates injectionsofANESTHESIA whichresultsinPAINandNUMBLIPS. In addition, the lack of feeling from the numbing injections can lead to THERMAL DAMAGE which can le
Slide 14: Why Dentists Should Buy an iPlus System?
Why Dentists Should Buy an iPlus System? …WaterLase’s Tremendous Return on Investment! Monthly Lease Payment New Monthly Revenue Generated Approx. $1,000 $5,000 – $15,000 • WaterLase technology enables traditional dentists to perform procedures that they currently refer out to specialists or current
Slide 15: Dental Schools Teaching WaterLase Technology around the World
Some of the Many Dental Schools that are Teaching WaterLase Technology around the World PAGE 15
Slide 16: Intellectual Property
Intellectual Property Award winning IP: Recognized for innovation, leadership, and the development of numerous disruptive technologies, most notably the development of a new surgical system to cut human tissue in a biological and atraumatic way. Received Astrum Award at MDB Capital’s 2011 Bright Lig
Slide 17: Patent Portfolio
Patent Portfolio Current Status: BIOLASE currently has 279 issued and pending patents, 70% of which are related to our core Er;Cr:YSGG technology and medical lasers. Issued Pending Total U.S. 84 46 130 International 74 75 149 Total 158 121 279 Filing costs and maintenance are closely monitored. Fund
Slide 18: iPlus Adoption is Accelerating
iPlus Adoption is Accelerating BIOLASE had broken the speed barrier with the revolutionary iPlus! • Prior to 1Q11 WaterLase adoption was thwarted by indirect sales through Henry Schein… – Began transition to direct sales model with 17 sales people in 4Q10. – Direct sales force of 31 at the end of 3Q
Slide 19: How BIOLASE is Positioned in the Dental Market
How BIOLASE is Positioned in the Dental Market BIOLASE United States BIOLASE International 5,700 2,700 6,800 2,800 Hard-tissue Hard-tissue Soft-tissue Soft-tissue Total: 12,500 Total: 5,500 Grand Total: 18,000 PAGE 19
Slide 20: $50B - $100B iPlus Market Opportunity
$50B - $100B iPlus Market Opportunity The iPlus’ globalmarketopportunityisimmense… because thedentalcommunity is thelargestmedical community in the world. Our current market penetration is approximately 3% in the US and slightly less than 1% internationally! 1 • 176,000 dentists in the US and Canada
Slide 21: Substantial Opportunity in Emerging Markets
Substantial Opportunity in Emerging Markets 1 Practicing Dentists Western Europe Eastern Europe 240,000dentists 120,000dentists 1 dentist / 1,800 population 1 dentist / 4,000 population China North America 16,000 dentists 176,000 dentists Middle East 1 dentist / 82,300 population 1 dentist / 1,900 p
Slide 22: Eliminating the Risk of Cross Contamination
Eliminating the Risk of Cross Contamination BIOLASE will enter new dental category utilizing WaterLase technology as it essentially eliminates the risk of cross contamination and contagion: Burs and Endo Files: WaterLase Tips: WaterLase MD™ reduced E. faecalis 2.86 times more effectively than NaOCl³
Slide 23: Patients Urged to Ask Dentists About Cross Contamination
Warning:Patients Urged to Ask their Dentists About the Risk of Cross Contamination! Cross contamination is a huge1,2,3,4 threat : • The CDC defines cross-contamination as the act of spreading bacteria and viruses from one surface to another. Blood-borne viruses have the ability to live on objects an
Slide 24: Further Opportunities to Expand in Dentistry
Further Opportunities to Expand in Dentistry Patented laser toothbrush for Home Use • BIOLASE is currently developing a laser toothbrush for consumer home-use in connection with a license agreement with The Proctor and Gamble Company (“P&G”). • Research indicates that a laser toothbrush for home-use
Slide 25: Diversification in 2012
Diversification in 2012 BIOLASE will diversify in 2012 and expand product sales beyond dentistry. 2011 (Projected) 2012 (Projected) WaterLase Systems ~64% ~50% Diode Systems ~15% ~15% Consumables & Other ~20% ~20% New ~1% ~15% • iPlus sales will continue grow rapidly as new products ramp enhancing r
Slide 26: 2012: Expanding Beyond Dentistry
2012: Expanding Beyond Dentistry WithourpatentedWaterLase anddiodetechnologies, wehavecreatedtechnological platformsthathavetheabilitytoextendfaroutsideofdentistry. Weexpecttogreatlyexpandouraddressable marketsinthecomingyearswhich,we believe,hasthepotentialto substantially increaseourrevenues.Eacho
Slide 27: 2012: Expanding Beyond Dentistry (Continued)
2012:Expanding BeyondDentistry(Continued) PainManagement: Weanticipatelaunching a newdeep-tissue handpieceandupgraded laserforpain therapyin2012whichwillcoincidewitha newmarketing campaign. Podiatry: WehavefoundthatourDiolase10technology isveryeffectiveinthetreatmentofnailfungus andwearecompleting t
Slide 28: Quarterly Revenues
QuarterlyRevenues (inMillions) Federico Pignatelli restored as Chairman & CEO in Aug 2010 Record quarter with Over 100% revenue Federico Pignatelli interim growth to date in 2011 CEO during Q407 Direct sales ramp begins in Sep 2010 compared to 2010 2004 2005 2006 2007 2008 2009 2010 2011 Q1-Mar $ 14
Slide 29: Quarterly Non-GAAP Net Income
QuarterlyNon-GAAP NetIncome(inMillions) Federico Pignatelli restored as Chairman & CEO in Aug 2010 2004 2005 2006 2007 2008 2009 2010 2011 Q1-Mar $ 0.783 $ (4.015) $ (1.462) $ (0.890) $ 0.985 $ (3.763) $ (4.797) $ 0.153 Q2-Jun $ 1.006 $ (6.222) $ (1.340) $ (0.089) $ 1.578 $ 3.020 $ (3.657) $ 0.069 Q
Slide 30: Financial Highlights
Financial Highlights Insider Purchases: During 2011, officers and directors have purchased approximately 109,700 shares of stock in the open market for approximately $440,000. In addition, officers and current and past directors have converted approximately 523,000 options into shares of common stoc
Slide 31: Chart & Financial History
Chart & Financial History 1994-2006 Pignatelli Aug 2010-Present Exclusive distribution partnership with Pignatelli CEO & Chairman of the Board Henry Schein Aug 2006–Aug 2010Board Chairman 20 BLTI Revenues BLTI 15 Share Price 1998 FDA Clearance 10 WaterLase 5 Volume: Millions of Shares PAGE 31
Slide 32: BIOLASE Technology, Inc. Today
BIOLASE Technology, Inc. Today BIOLASE is the Global Leader in Dental Lasers: • Our 57,000 sq. ft. corporate HQ in Irvine houses administrative, sales, marketing, customer care, training, manufacturing, and R&D. This facility can accommodate growth to $250 million. • We also have manufacturing capab
Slide 33: Recent Developments
Recent Developments StockDividend: InNovember 2011,BIOLASE’s Boardof Directorsdeclareda 1%stockdividendto shareholders of recordonNovember25,2011,payableonDecember 5,2011.Thisisthefourth1% stock dividend declared by the Board during 2011. RecentApprovals: Recentlyreceivedregulatory approvalstosellth
Slide 34: Recent Developments (continued)
RecentDevelopments (continued) DirectSalesinGermany: BIOLASE hasregainedtheabilitytoselldirector throughother distributors fromHenryScheinInc.(NASDAQ: HSIC)forallofitsinternationalterritories andhas announced planstoexpandBIOLASE Europe,GMBH,tonowincludea directsalesforce,along withserviceandsupport
Biolase Technology — Lazard 8th Annual Healthcare Conference (November 2011) on 6ix